地西他滨治疗骨髓增生异常综合征的临床疗效研究

目的通过对比地西他滨与传统的联合化疗在骨髓增生异常综合征(MDS)治疗中的各项指标,从而对地西他滨的临床疗效做出评价。方法纳入MDS患者26例,11例接受地西他滨5 d方案治疗(地西他滨组),15例患者接受三尖杉酯碱+阿糖胞苷(HA)、柔红霉素+阿糖胞苷(DA)联合化疗(联合化疗组)。比较两组患者治疗前的基线情况、治疗后的疗效及不良反应发生情况。结果治疗后地西他滨组患者总缓解率为45.5%,总有效率为72.7%,无效率为27.3%;联合化疗组总缓解率为46.7%,总有效率为73.3%,无效率为26.7%,两组患者的缓解率差异无统计学意义(χ2=0.308,P0.05),有效率差异也无统计学意义(χ2=0.973,P0.05)。地西他滨组不良反应发生率为27.3%,联合化疗组不良反应发生率为46.7%,两组患者的不良反应发生率差异具有统计学意义(χ2=3.009,P0.05)。结论地西他滨用于骨髓异常增生综合征的治疗与传统联合化疗治疗效果相当,不良反应发生率低于联合化疗,适合应用于骨髓异常增生综合征高危患者的治疗。

Clinical analysis of decitabine in the treatment of myelodysplastic syndrome.

Objective To compare the indexes of decitabine and combination chemotherapy treatment in the treatment of myelodysplastic syndrome （MDS）, so as to evaluate the clinical efficacy of decitabine. Methods A total of 26 patients with MDS were collected. 11 patients received decitabine treatment, and 15 patients received combined treatment of HA and DA. The treatment of decitabine used 5d regimen. The efficacy and adverse effects of the two groups were compared. Results For patients receiving decitabine treatment, the total remission rate was 45.5%, the total effective rate was 72.7%, and the ineffective rate was 27.3%. For the combined treatment of HA and DA, the total remission rate was 46.7%, the total effective rate was 73.3%, and the ineffective rate was 26.7%. There was no significant difference in the total remission rate between the two groups （ χ2 = 0. 308, P 〉 0.05 ）. There was no significant difference in the total effective rate between the two groups （ χ2 = 0. 973, P 〉 0.05）. The rate of adverse effect of decitabine treatment was 27.3%, and it was 46.7% for HA and DA treatment. There was significant difference in the adverse effect between the two groups （ χ2 = 3. 009, P 〈 0.05 ）. Conclusion The efficacy of decitabine and combination chemotherapy treatment was similar, and the adverse effect of decitabine was lower than combination chemotherapy. Decitabine was suitable for patients with MDS.